These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1445752)

  • 1. In vitro and in vivo antitumoral activity of alkylphosphonates.
    Ries UJ; Fleer EA; Breiser A; Unger C; Stekar J; Fenneberg K; Eibl H
    Eur J Cancer; 1992; 29A(1):96-101. PubMed ID: 1445752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.
    Bishop FE; Dive C; Freeman S; Gescher A
    Cancer Chemother Pharmacol; 1992; 31(2):85-92. PubMed ID: 1451237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
    Unger C; Damenz W; Fleer EA; Kim DJ; Breiser A; Hilgard P; Engel J; Nagel G; Eibl H
    Acta Oncol; 1989; 28(2):213-7. PubMed ID: 2736110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor heterogeneity and chemosensitivity to cyclophosphamide, vinblastine and hexadecylphosphocholine.
    Angres G; Scherf HR; Schmähl D
    Cancer Treat Rev; 1990 Sep; 17(2-3):339-45. PubMed ID: 2272049
    [No Abstract]   [Full Text] [Related]  

  • 5. Hexadecylphosphocholine: a new and selective antitumor drug.
    Eibl H; Unger C
    Cancer Treat Rev; 1990 Sep; 17(2-3):233-42. PubMed ID: 2272038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
    Hilgard P; Klenner T; Stekar J; Nössner G; Kutscher B; Engel J
    Eur J Cancer; 1997 Mar; 33(3):442-6. PubMed ID: 9155530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexadecylphosphocholine: preclinical and the first clinical results of a new antitumor drug.
    Unger C; Eibl H
    Lipids; 1991 Dec; 26(12):1412-7. PubMed ID: 1819743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo.
    Sobottka SB; Berger MR; Eibl H
    Int J Cancer; 1993 Feb; 53(3):418-25. PubMed ID: 8428795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.
    Kaufmann-Kolle P; Berger MR; Unger C; Eibl H
    Adv Exp Med Biol; 1996; 416():165-8. PubMed ID: 9131143
    [No Abstract]   [Full Text] [Related]  

  • 10. Alkylphosphocholines: a new class of membrane-active anticancer agents.
    Hilgard P; Klenner T; Stekar J; Unger C
    Cancer Chemother Pharmacol; 1993; 32(2):90-5. PubMed ID: 8485813
    [No Abstract]   [Full Text] [Related]  

  • 11. Alkyl phosphocholines: toxicity and anticancer properties.
    Muschiol C; Berger MR; Schuler B; Scherf HR; Garzon FT; Zeller WJ; Unger C; Eibl HJ; Schmähl D
    Lipids; 1987 Nov; 22(11):930-4. PubMed ID: 3444388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexadecylphosphocholine does not influence phospholipase D and sphingomyelinase activity in human leukemia cells.
    Berkovic D; Berkovic K; Binder C; Haase D; Fleer EA
    J Exp Ther Oncol; 2002; 2(4):213-8. PubMed ID: 12416025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of alkylphosphonates, a new class of antineoplastic agents.
    Ries UJ; Fleer EA; Eibl H
    Chem Phys Lipids; 1992 May; 61(3):225-34. PubMed ID: 1525962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).
    Hilgard P; Stekar J; Voegeli R; Engel J; Schumacher W; Eibl H; Unger C; Berger MR
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1457-61. PubMed ID: 3141197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats.
    Scherf HR; Schuler B; Berger MR; Schmähl D
    Lipids; 1987 Nov; 22(11):927-9. PubMed ID: 3444387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine.
    Kaufmann-Kolle P; Drevs J; Berger MR; Kötting J; Marschner N; Unger C; Eibl H
    Cancer Chemother Pharmacol; 1994; 34(5):393-8. PubMed ID: 8070005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexadecylphosphocholine differs from conventional cytostatic agents.
    Berger MR; Betsch B; Gebelein M; Amtmann E; Heyl P; Scherf HR
    J Cancer Res Clin Oncol; 1993; 119(9):541-8. PubMed ID: 8392075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineoplastic activity in vitro of free and liposomal alkylphosphocholines.
    Zeisig R; Jungmann S; Arndt D; Schütt A; Nissen E
    Anticancer Drugs; 1993 Feb; 4(1):57-64. PubMed ID: 8457716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.
    Bruyneel EA; Storme GA; Schallier DC; Van den Berge DL; Hilgard P; Mareel MM
    Eur J Cancer; 1993; 29A(14):1958-63. PubMed ID: 8280489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas.
    Berger MR; Yanapirut P; Reinhardt M; Klenner T; Scherf HR; Schmeiser HH; Eibl H
    Prog Exp Tumor Res; 1992; 34():98-115. PubMed ID: 1438807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.